Ocular begins patient enrolment in dexamethasone Phase II trial for dry eye disease

US-based biopharmaceutical firm Ocular Therapeutix has started patient enrolment in a Phase II clinical trial of sustained release dexamethasone (OTX-DP), an ophthalmic corticosteroid to treat inflammatory dry eye disease.

Category One, Showcase, status, Uncategorized, What's Hot